oAs of May 18, 2021, 36 US states and four territories allow for the medical use of cannabis products.
Current evidence from global database registries and other patient reported outcomes incorporate information from thousands of patients, but much of the evidence is based on anecdotal reports
rather than possessing the robustness of randomized clinical trials, and these different types of sources are not always in agreement.
As many patients are already using cannabis products for medicinal applications, it is important to identify the evidence that exists and as it evolves, and to harmonize and coordinate this information to maximize the potential benefits to patients while minimizing harmful effects.
The goal of this cannabis registry is to gather information regarding medicinal cannabis products used as well as timing of, reasons for, and outcomes of use and impacts on other non-cannabis medication (e.g., opioids) use.
This coordinating center will also lead efforts in archiving and analyzing these data, as well as disseminating their findings.